172@29@17@247!~!172@29@0@53!~!|news|cipla|management-interviews-C-6months.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
you are here: HomeNewsCipla
management interviews
Jump to
43 Results Found
  • Interview: How Cipla plans to bounce back after a weak Q2 Nov 08, 2018 01:08 PM IST

    Interview: How Cipla plans to bounce back after a weak Q2

    In an interview with Moneycontrol, Kedar Upadhye, Global Chief Financial Officer of Cipla, talked about the company's strategy going forward.

  • Revenue is a challenge for us; little concerned about revenue growth: Cipla Mar 01, 2018 03:22 PM IST

    Revenue is a challenge for us; little concerned about revenue growth: Cipla

    India is a sizeable market for us. Our growth story is intact in our core markets. I am not unduly concerned about growth trajectories within our core markets, said Umang Vohra, MD & Global CEO of Cipla.

  • US, India will continue to outperform going ahead: Cipla Feb 08, 2018 11:57 AM IST

    US, India will continue to outperform going ahead: Cipla

    In an interview with CNBC-TV18, Kedar Upadhye, Group CFO of Cipla spoke about the results and his outlook for the company.

  • See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla Nov 17, 2017 01:24 PM IST

    See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla

    The US remains the largest market in the world and they look at it as an attractive opportunity, Umang Vohra, MD & Global CEO, Cipla.

  • Will continue to pursue inorganic growth in India & US: Torrent Pharma Nov 07, 2017 12:19 PM IST

    Will continue to pursue inorganic growth in India & US: Torrent Pharma

    In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

  • New draft pharma policy will reduce risks like generalisation of mkt: JM Financial Sep 15, 2017 04:04 PM IST

    New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

    In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.

  • Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality Aug 17, 2017 01:10 PM IST

    Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality

    In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.

  • Expect to see 18-20% growth for FY18: TCI Express Jun 01, 2017 04:21 PM IST

    Expect to see 18-20% growth for FY18: TCI Express

    In an interview to CNBC-TV18, Chander Agarwal, MD & CEO, TCI Express spoke about the results and his outlook for the company.

  • Cipla to remain unfazed by Trump's protectionist policy Mar 02, 2017 01:33 PM IST

    Cipla to remain unfazed by Trump's protectionist policy

    Umang Vohra of Cipla reasoned that almost 80 percent of the drugs sold by Cipla in the US market are manufactured in the US itself. He said it will not be a challenge to manufacture all its supplies in the US itself if asked to do so by authorities.

  • Looking for bigger partnership with Cipla: Serum Institute Jan 21, 2017 02:51 PM IST

    Looking for bigger partnership with Cipla: Serum Institute

    Adar Poonawala, CEO of Serum Institute, believes that a bigger partnership with Cipla will create a big Indian conglomerate. However, he added that the Cipla promoters currently have no plans for a merger and acquisition.

  • Expect 10-15 launches in the US this year: Cipla May 25, 2016 10:59 AM IST

    Expect 10-15 launches in the US this year: Cipla

    Initiatives are underway to normalise operations and the management is committed to making its EBITDA trajectory more sustainable in FY17, says Umang Vora, Global COO, Cipla.

  • Indian pharma cos need to step-up safeguards at plants: Handa Mar 29, 2016 09:29 PM IST

    Indian pharma cos need to step-up safeguards at plants: Handa

    In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

  • 20% of Cipla FY17 revenues to come from US: Chirag Talati Feb 23, 2016 01:47 PM IST

    20% of Cipla FY17 revenues to come from US: Chirag Talati

    When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

  • Cipla completes acquisition of US cos InvaGen and Exelan Feb 18, 2016 11:48 AM IST

    Cipla completes acquisition of US cos InvaGen and Exelan

    In an interview with CNBC-TV18, Umang Vohra, COO of Cipla said that the company‘s current growth guidance did not include this merger and it will be a part of it in the next fiscal.

  • Sub-license for Hepatitis C drug beneficial for patients: Cipla Jan 21, 2016 11:23 AM IST

    Sub-license for Hepatitis C drug beneficial for patients: Cipla

    Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.

  • Cipla to pay for InvaGen, Exelan mostly through own funds Sep 04, 2015 09:46 AM IST

    Cipla to pay for InvaGen, Exelan mostly through own funds

    Cipla Global Chief Executive Officer Subhanu Saxena said both acquisitions would add to Cipla's earnings from Day One, and that the acquisition would give the company a strong platform to accelerate growth in US.

  • Aiming to achieve 70-80% organic growth: Cipla Aug 27, 2015 09:17 PM IST

    Aiming to achieve 70-80% organic growth: Cipla

    The pharma major's MD and CEO Subhanu Saxena says the company is aiming at achieving a growth of 70-80 percent growth without making any major acquisitions in the near future.

  • Consumer health mkt growing at high double digit: Cipla Jul 21, 2015 10:06 PM IST

    Consumer health mkt growing at high double digit: Cipla

    Calling consumer healthcare to be an exciting space for the company, Chandru Chawla, the head of Cipla, New Ventures says: "Consumer health market in India is upwards of USD 4 billion today and is growing at a very high double digit."

  • See Rs 400cr increase in top line over next few yrs: Hetero Mar 24, 2015 03:29 PM IST

    See Rs 400cr increase in top line over next few yrs: Hetero

    The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.

  • What a potential Cipla-Serum merger could mean Feb 06, 2015 05:16 PM IST

    What a potential Cipla-Serum merger could mean

    Billionnaire Cyrus Poonawalla, founder of the world‘s biggest vaccine maker Serum Institute, has told CNBC-TV18 that after the company tied up with drugmaker Cipla to sell its vaccines in Europe late last year, Serum is now exploring the option of merging with it.

  • Serum Institute in 'initial talks' to explore Cipla merger Feb 06, 2015 05:05 PM IST

    Serum Institute in 'initial talks' to explore Cipla merger

    After tying up with drugmaker Cipla to market its products last year, the Poonawalla Group's Serum Institute, the world's largest vaccine maker, is considering the option of merging with it.

  • Sun's margins may reduce to 30-32% post merger: Surajit Pal Dec 29, 2014 12:36 PM IST

    Sun's margins may reduce to 30-32% post merger: Surajit Pal

    As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

  • Discussing partnerships, have done in-licensing deals:Cipla Sep 29, 2014 07:11 PM IST

    Discussing partnerships, have done in-licensing deals:Cipla

    The company's CEO, Subhanu Saxena, in an exclusive conversation with CNBC-TV18's Archana Shukla says the focus is on building the company for the long term.

  • Aiming growth of USD 3-4 bn by 2020: Cipla Feb 19, 2014 06:31 PM IST

    Aiming growth of USD 3-4 bn by 2020: Cipla

    On the days to come, Yusuf Hamied, chairman, Cipla, says the pharma major may open units in foreign countries just like its peers.

  • FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla Feb 13, 2014 10:18 AM IST

    FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla

    Rajesh Garg, global chief financial officer, Cipla, told CNBC-TV18 that operating profits were impacted in the absence of anti-depressant Escitalopram sales in the US, and higher sales of anti-retroviral (ARV) drugs, where profit margins are low.

Sections